NCT06476379

Brief Summary

There is evidence indicating that sperm plays a role in determining blastocyst ploidy status. In our study, we aim to compare the outcomes of preimplantation genetic testing for aneuploidy (PGT-A) and the subsequent clinical outcomes following transfers of euploid embryos. This comparison will be conducted between cases where ejaculated sperm and cases where testicular sperm were used for intracytoplasmic sperm injection (ICSI), specifically focusing on severe male factor infertility patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 21, 2024

Completed
4 days until next milestone

Study Start

First participant enrolled

June 25, 2024

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 26, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
Last Updated

August 15, 2025

Status Verified

June 1, 2024

Enrollment Period

10 months

First QC Date

June 21, 2024

Last Update Submit

August 14, 2025

Conditions

Keywords

ICSIMale infertilityPGT-ATESE

Outcome Measures

Primary Outcomes (8)

  • Euploidy rate

    Defined as the proportion of euploid blastocysts

    15 days post ICSI

  • Aneuploidy rate

    Defined as the proportion of aneuploid blastocysts

    15 days post ICSI

  • Low mosaic rate

    Defined as the proportion of low mosaic blastocysts

    Time Frame: 15 days post ICSI

  • High mosaic rate

    Defined as the proportion of high mosaic blastocysts

    Time Frame: 15 days post ICSI

  • Implantation rate

    defined as the percentage of successfully implanted embryos

    6-9 weeks post-embryo transfer

  • Ongoing pregnancy rate

    defined as a positive heartbeat on ultrasound beyond 12 weeks of gestation

    12 weeks of gestation

  • Miscarriage rate

    defined as pregnancy loss following confirmation of clinical pregnancy

    after 6 weeks of gestation

  • Clinical pregnancy rate

    defined as the presence of a fetal heartbeat or gestational sac 6-9 weeks post-embryo transfer

    6-9 weeks post-embryo transfer

Secondary Outcomes (3)

  • Fertilization rate

    1 day

  • Cleavage rate

    3 days

  • Blastocyst development rate

    5-6 days

Study Arms (2)

Ejaculate

ACTIVE COMPARATOR

Patients within this arm will undergo ICSI utilizing ejaculated sperm.

Other: Ejaculate

Testicular

ACTIVE COMPARATOR

Patients within this arm will undergo ICSI utilizing testicular sperm.

Procedure: Testicular sperm extraction (TESE)

Interventions

Surgical procedure used to retrieve sperm directly from the testicles of men who have low sperm production or no sperm in their ejaculate

Testicular

Ejaculate processing for ICSI

Ejaculate

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Cases planned to have ICSI PGT-A cycles
  • Males diagnosed as severe male factor infertility
  • Normo responder female partners

You may not qualify if:

  • Leukocytospermia
  • Presence of varicocele.
  • Known genetic abnormality
  • Use of sperm or oocyte donors
  • Use of gestational carrier
  • Presence of any of the endometrial factors that affect embryo implantation such as hydrosalpings, adenomyosis or previous uterine infection
  • Any contradictions to undergoing in vitro fertilization or gonadotropin stimulation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ganin Fertility Center

Cairo, Maadi, 11728, Egypt

Location

MeSH Terms

Conditions

Infertility, Male

Condition Hierarchy (Ancestors)

Genital Diseases, MaleGenital DiseasesUrogenital DiseasesInfertilityMale Urogenital Diseases

Study Officials

  • Eman Hasanen

    Ganin Fertility Center

    PRINCIPAL INVESTIGATOR
  • Hosam Zaki, FRCOG

    Ganin Fertility Center

    STUDY CHAIR
  • Refaat Gabre, PhD

    Faculty of Science, Cairo University

    STUDY DIRECTOR
  • Mohamed Abbas

    Cairo University

    STUDY CHAIR
  • Nahla Osama, Phd

    Faculty of Science, Cairo University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 21, 2024

First Posted

June 26, 2024

Study Start

June 25, 2024

Primary Completion

April 30, 2025

Study Completion

April 30, 2025

Last Updated

August 15, 2025

Record last verified: 2024-06

Locations